Save up to 90% on Vyndaqel with Coupons, Discount Cards & Patient Assistance Programs

Vyndaqel is the brand name for tafamidis meglumine and is available as an oral capsule.

Vyndaqel is available as a 20 mg oral capsule.

Vyndaqel is a transthyretin (TTR) stabilizer that is used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, a rare heart muscle disease).

Vyndaqel is a transthyretin (TTR) stabilizer. It works by attaching to a protein in your body called transthyretin. This slows protein breakdown and buildup in the heart walls, which makes it easier for the heart to pump blood to the rest of your body.

Vyndaqel is typically taken as 80 mg by mouth once daily.

Vyndaqel is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Vyndaqel:

• Bone, muscle, or joint problems
• Injury
• Skin problems
• Heart failure
• Falls
• Mental health problems
• Atrial fibrillation
• Shortness of breath
• Swelling of the hands, feet, or ankles
• Tiredness
• Dizziness
• Eye problems
• Constipation

Serious side effects are rare with Vyndaqel.

The following medications may interact with Vyndaqel:

• Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate

Pfizer Inc.

Vyndaqel may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Vyndaqel or VYNDAMAX. You may also report your pregnancy by calling the Pfizer reporting line at 1-800-438-1985.

• Tafamidis Meglumine